Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X

Publications

Single-cell mutational profiling enhances the clinical evaluation of AML MRD


Asiri Ediriwickrema, Alexey Aleshin, Johannes G. Reiter, M. Ryan Corces, Thomas Köhnke, Melissa Stafford, Michaela Liedtke, Bruno C. Medeiros, Ravindra Majeti
Blood Advances Mar 2020
Abstract

Although most patients with acute myeloid leukemia (AML) achieve clinical remission with induction chemotherapy, relapse rates remain high. Next-generation sequencing enables minimal/measurable residual disease (MRD) detection; however, clinical significance is limited due to difficulty differentiating between pre-leukemic clonal hematopoiesis and frankly malignant clones. Here, we investigated AML MRD using targeted single-cell sequencing (SCS) at diagnosis, remission, and relapse (n = 10 relapsed, n = 4 nonrelapsed), with a total of 310 737 single cells sequenced. Sequence variants were identified in 80% and 75% of remission samples for patients with and without relapse, respectively. Pre-leukemic clonal hematopoiesis clones were detected in both cohorts, and clones with multiple cooccurring mutations were observed in 50% and 0% of samples. Similar clonal richness was observed at diagnosis in both cohorts; however, decreasing clonal diversity at remission was significantly associated with longer relapse-free survival. These results show the power of SCS in investigating AML MRD and clonal evolution.

VIEW

Area

Heme

Institution Type

Academia

Indication / Modality

Acute Myleoid Leukemia, Acute Myleoid Leukemia (AML)

Goal of Study

Clinical Profiling, Clonal Evolution, Clonal Heterogeneity, Clinical Trial, MRD, CHIP

PAD Project

No

Tissue / Organ

Bone Marrow Aspirates

Species

Human
REQUEST QUOTE